Evidence from cell line-based studies indicates that q-kinase may play a role in the leukaemic transformation of human cells mediated by the BCR/ABL tyrosine kinase, manifest clinically as chronic myeloid leukaemia (CML). We therefore employed two separate inhibitors, Y-27632 and fasudil, to inhibit the activity of q-kinase against ex vivo CD34 þ cells collected from patients with CML. We compared the effects of q-kinase inhibition in those cells with the effects of direct inhibition of BCR/ABL using the specific inhibitor imatinib. We found that inhibition of q-kinase inhibited the effective proliferation, and reduced survival of CML progenitor cells. When combined with imatinib, q-kinase inhibition added to the anti-proliferative and pro-apoptotic effects of the BCR/ABL inhibitor. Our studies may indicate therapeutic benefit in some cases for the combination of q-kinase inhibitors with imatinib.
Introduction
Chronic myeloid leukaemia (CML) can be effectively treated using inhibitors of the activated protein tyrosine kinase BCR/ ABL. Following treatment with imatinib mesylate (imatinib), the majority of patients achieve full cytogenetic remission, and a significant proportion of those treated will enter a molecular remission. 1 However, imatinib does not eliminate the CML clone, and clinical resistance to the drug is a major source of treatment failure. 2 There is, therefore, a clinical need for additional therapeutic agents. In the present paper we report the biological effects of the inhibition of r-kinase in CML cells, and suggest that drugs that inhibit r-kinase may have therapeutic potential in the treatment of CML. The basis for this study was the observation that the phosphorylation of r-GDI was reduced in cells that expressed BCR/ABL.
3 r-GDI acts as a control for the activation of r-GTPase: r-GDI binds to, and stabilizes, its substrate (r-GDP) within the cytosol. When dephosphorylated r-GDI releases r-GDP, this allows the formation of the active form of the molecule r-GTP. r-GTP is then translocated to its active site at the cell membrane where it interacts with, and activates, specific targets including r-kinase (r-associated protein kinase 1, coiled-coil containing protein kinase 1, ROCK 1). 4 We postulated, therefore, that r-kinase may be constitutively activated in CML cells and, as such, may play a role in the dysregulated growth that characterizes the disorder. In this regard, it is pertinent that signals generated by the r-kinase pathway govern interactions between the cell and its environment. In particular, r-kinase is known to recruit important mediators of actin polymerization, and to cause clustering of integrin receptors and the formation of focal adhesions. 5, 6 Those functions may be highly relevant to the abnormal proliferation of CML cells, since altered focal adhesion formation and altered integrin activation have been linked to the abnormal proliferative behaviour of CML. 7, 8 In the present paper, we show, using specific inhibitors, that the inhibition of r-kinase opposes the proliferation of CML CD34 þ progenitor cells by enhancing cellular apoptosis and opposing cell cycle progression. The observed growth inhibition is relatively specific for CML cells, and the effects are synergistic with the effects of imatinib.
Methods

Patients and samples
All patient and normal marrow samples were obtained with informed consent from patients presenting to Manchester Royal Infirmary. In all cases, heparinized samples were collected before any therapy was initiated. Mononuclear cells were initially isolated using ficoll density gradient centrifugation (density 1.077 g/ml, Amersham Biosciences, Little Chalfont, UK) according to standard protocols. Cells were then washed by centrifugation. In some experiments fresh cells were employed, where this was not possible, cells were re-suspended in 90% (v/v) fetal calf serum (FCS, Life Technologies, Paisley, UK) and 10% (v/v) dimethyl sulfoxide, and were frozen in liquid nitrogen until use. In all cases, cytogenetic analysis showed more than 90% of cells expressed the Philadelphia chromosome. All cases used had typical clinical and morphological features of chronic phase CML. No case employed in this study showed clinical resistance to imatinib therapy.
Chemicals and reagents
General chemicals were obtained from Sigma-Aldrich (Poole, UK). Tissue culture plastic was from Corning Costar (High Wycombe, UK). Flow cytometry reagents were obtained from Becton Dickinson (Oxford, UK) unless otherwise indicated. The following signal transduction inhibitors were used: imatinib was a gift from Novartis, Switzerland. Y-27632 and fasudil were purchased from Tocris Cookson (Bristol, UK). The optimal time course, and effective dose, for each inhibitor was determined by titration experiments initially in cell lines 3 then using the primary CML CD34
þ cells employed in this study. In all cases, inhibitors were added when the experiment was initiated using the final concentrations indicated in the text.
Cell preparation
Stored cells were gently thawed by drop-wise addition of Hank's balanced salt solution plus 5% (v/v) newborn calf serum (Life Technologies). Viability and CD34 þ count was determined for each patient, and cases with high viability and CD34 count were selected for study. CD34 þ cells were then selected using positive selection by immunomagnetic beads (MiniMacs CD34 cell isolation kit, Miltenyi Biotech, UK) according to manufacturer's protocols. Following this procedure the mean CD34 expression of samples after isolation determined by flow cytometry was 92% (range 87-97%). Samples were also tested for viability using trypan blue exclusion according to standard protocols. Soft gel colony-forming assays were performed as previously described. 9 Liquid culture system Cells were subsequently cultured at 371C in 5% CO 2 in Iscoves Medium (Life Technologies) using 20% FCS (ICN 'Gold' serum, ISN Biomedicals, Basingstoke, UK). Cytokines were added, on the first day of culture only, at the following concentrations: granulocyte monocyte colony-stimulating factor 10 ng/ml (R&D systems, Minneapolis, MN, USA), granulocyte colony-stimulating factor 5 ng/ml (Calbiochem, Merk, Nottingham, UK), interleukin-3 0.2 ng/ml (a gift from Sandoz Pharmaceuticals, Basel, Switzerland), stem cell factor 100 ng/ml (Amgen, Thousand Oaks, CA, USA). The serum employed was previously determined, by in-house testing of multiple sera, to be optimal for granulocyte/macrophage colony formation in colony-forming assays. Cytokine concentrations were selected for their ability to induce granulocytic differentiation in our in vitro system.
Flow cytometric analyses
Flow cytometry employed a FACS Vantage Flow Cytometer (Becton Dickinson). All flow cytometry reagents were obtained from Becton Dickinson/Pharmingen (Oxford, UK). Differentiation assessment employed directly conjugated monoclonal antibodies as indicated. The following fluorochrome-conjugated antibodies were obtained from Becton Dickinson: phycoerythrin conjugates CD34, CD13; fluorescein isothiocyanate (FITC) conjugates CD15 and lineage markers (CD2, CD14, CD15, CD19) employed at the manufacturer's recommended concentrations. Apoptosis was determined by flow cytometry using dual-colour fluorescence of Annexin V/propidium iodide according to the manufacturer's protocols. Annexin V-FITC was obtained from R&D Systems and propidium iodide was obtained from Molecular Probes (Cambridge BioScience, Cambridge, UK). BrDU analysis employed 5-bromo-2 0 -deoxyuridine (BrDU) (Sigma) according to standard protocol. Briefly, cultured cells were pulse labelled with BrDU, and at appropriate time periods were removed from culture, fixed, permeabilized and labelled with anti-BrDU-FITC (Becton Dickinson) and with propidium iodide (Cambridge Bioscience). Labelled cells were then analysed using flow cytometry as indicated.
Microscopy
For morphological testing, cytospins were prepared using 3 Â 10 4 cells per slide (Cytospin 2, Shandon, Runcorn, UK) using standard protocols. Cytospins were air dried overnight then stained using May-Grunwald Giemsa. Cells were examined using a Leica DMR microscope (Leica Microsystems A.G., Heerbrugg, Switzerland), and morphology was assessed. Images were captured using a Coolsnap CCD camera (RS Photometrics, Tuscan, AZ, USA) and MetaView software (Universal Imaging Corporation, Marlow, UK).
Results and discussion
The effect of inhibition of r-kinase on CML cells was first tested using the selective inhibitor Y-27632, then with the second clinically active inhibitor fasudil. Both agents have a relatively high specificity for r-kinase, 10 and have been employed as r-kinase inhibitors by ourselves, 3 and by others, in cell types including haematopoietic cells. 11 In our earlier studies using cell line Y-27632 (50 mM) was found to have the same in vitro activities as a dominant negative r, further confirming its specificity. 3 Since CML progenitors mature in vivo in the presence of exogenous growth factors, and it is believed that altered sensitivity to growth factors may play a role in the abnormal growth of CML cells, 12 we studied the growth of progenitor cells during cytokine-stimulated growth and maturation. Moreover, as r-kinase is only one of a wide range of potential downstream targets activated by BCR/ABL, 13 we compared the effects of r-kinase inhibition with direct inhibition of BCR/ABL using imatinib. Colony assays were initially applied. We found that inhibition of r-kinase by Y-27632 selectively inhibited the colony growth of CML cells (Po0.05 Wilcoxen signed-rank test for nonparametric data, n ¼ 5) ( Figure 1A ). In contrast, when normal CD34 þ cells were tested, there was reduced colony growth but this was not statistically significant: mean colony was reduced by 24%, P ¼ NS The observed growth inhibition by the r-kinase inhibitor was similar in extent to that observed when imatinib (1 mM) was employed: mean inhibition colony growth of CML cells was 48% (Po0.05%) and inhibition of colony growth of normal cells was 20% (P ¼ NS; Wilcoxen signed-rank test). We then employed a liquid culture system. In the absence of inhibitors, the number of cells in CML CD34 þ cultures increased progressively (after 48 h mean expansion was 2.570.22-fold, n ¼ 6 cases). In the presence of Y-27632 (50 mM), mean expansion was reduced to 1.8370.2-fold; this was similar to that observed in the presence of imatinib (at a dose of 1 mM, expansion was 1.570.2-fold, n ¼ 6). When the drugs were combined, the effects were found to be additive (mean expansion 1.170.2-fold ( Figure 1B ). Statistical analysis (paired t-test for sample means) confirmed a significant inhibition using either drug alone (Po0.05); further significant growth inhibition was observed when the drugs were combined (Po0.05).
Enhanced survival mediated by BCR/ABL has been described in cell lines 14 and primary cells, 15 and it is well recognized that imatinib induces the apoptosis of CML cells independently of their proliferative status; 16 therefore, the effects of r-kinase inhibition were tested in relation to CML CD34 þ cell survival. Analysis of apoptosis used two flow cytometric methods: assay of pre-G1 peak of propidium iodide stained cells, and/or measurement of surface Annexin V expression (Figures 2A and  B, respectively) . Both methods suggested that Y-27632 caused a moderate increase in apoptosis. In control cultures the 'basal' rate of apoptosis was 18% (mean of 8 cases tested at 48 h). In the presence of Y-27632, the rate of apoptosis was increased to 26%. Consistent with its known activity, imatinib was also found to increase apoptosis to 26%. The observed increase in apoptosis was statistically significant for each drug (for Y-27632 P ¼ 0.012; for imatinib Po0.003, n ¼ 8 cases, t-test for means of paired samples). Additionally, when Y-27632 and imatinib were combined in culture, the level of apoptosis was 35%; this increase was significantly greater than when either drug when present alone (Po0.002, t-test for means of paired samples, n ¼ 8 cases), indicating an additive effect of the r-kinase inhibitor to the imatinib-induced apoptosis of CML cells.
Both r-kinase 17 and BCR/ABL 18, 19 are known to affect cell cycling. The incorporation of BrDU into newly synthesized DNA (BrDU analysis) was therefore employed to enable the assessment of CML cell proliferation. Briefly, sequential flow cytometric measurement was used to measure the incorporation of pulsed BrDU into newly synthesized DNA and this was analysed together with the total DNA content of cells. This analysis, therefore, allowed the identification of cells that did not enter division during the BrDU-labelling period (that is, had no detectable BrDU incorporation on flow cytometric analysis); cells that entered and completed division (that is, cells that incorporated BrDU, but had normal DNA content) and cells that incorporated BrDU but had not completed the G 2 /S phase or cytokinetic phase of cell division (that is, had high DNA content, indicated by increased propidium iodide fluorescence). Consistent with previous reports from others, 20 we showed that for imatinib-treated cultures, the entry of cells into cycle was reduced (undivided cells were 4176% in control cultures, compared to 5077% in imatinib-treated cultures; 9 comparisons in n ¼ 5 experiments, Po0.01). However, we found that those cells that entered cell division cycle showed comparable rates of progression to that seen in control cultures. In cultures treated with Y-27632 there was no reduction in the number of cells that entered cell division (the 'undivided' cell fraction was 4174% in control samples compared to 4174% of those treated with Y-27632; 9 comparisons in n ¼ 5 experiments). However in the presence of the r-kinase inhibitor, the proportion of cells completing effective mitosis in the 24 h was significantly reduced. This failure to complete cell cycle was due to an accumulation of cells with high DNA content (10.672% in control cultures; compared to 15.472.4% in Role q-kinase inhibitors and imatinib in CML J Burthem et al Y-27632-treated cultures, Po0.01 using t-test for sample means). When both drugs were present, the effects were combined. The entry into cell cycle was inhibited, and an accumulation of cells of high DNA content was again seen, resulting in fewer cells completing cell cycle than when either drug was present alone (Figure 3) . These results were confirmed by morphological assessment: when compared with control cultures a much larger proportion of cells could be seen actively in mitosis, additionally there was evidence of defective cytokinesis with significant numbers of bi-nucleate cells seen, and occasional cells with apparently disordered chromosomal segregation (representative cells from cytospin preparations are Role q-kinase inhibitors and imatinib in CML J Burthem et al shown in Figure 3) . In control cultures, the fraction of cells with visible chromosome segregation was 2.3%, with rare multinucleate forms (o1%); in the presence of Y-27632 the fraction of cells with chromosome segregation or multiple nuclei increased in a dose-dependant manner.
The differentiation of CML CD34 þ cells was also assessed after exposure to either Y-27632 or to imatinib. It was found that imatinib, but not Y-27632, caused a higher proportion of cells with features of differentiation to be present in comparison with control cultures. Flow cytometric assessment of markers of granulocytic maturation showed that in the presence of imatinib, CD13, a marker of early commitment to granulocytic maturation, was present at an earlier time point on maturing CML CD34 þ cells. At later time points, loss of CD13 expression, and the appearance of CD15 was observed in imatinib-treated cultures ( Figure 4A ). The increase in CD13 expression after 48 h was statistically significant (expression was seen on 72% of cells in control cultures, compared to 80% in cultures exposed to imatinib (Po0.05 using t-test of sample means of paired samples, n ¼ 5 cases). This effect of imatinib was confirmed by morphological assessment ( Figure 4B ). In the presence of imatinib a greater proportion of cells had more advanced morphological maturation. In contrast, cells treated with Y-27632 showed no increase in the number or proportion of mature cells formed.
The compound Y-27632 is unsuited to clinical use. However, an alternative inhibitor of r-kinase, fasudil, is active in vitro and in vivo, and has been used clinically in the treatment of patients with non-malignant disorders without reported toxicity in haematological cells. 21 We, therefore, also examined fasudil in preliminary experiments in parallel with Y-27632. When tested in colony assays (n ¼ 1), or using our in vitro liquid culture system, we found that fasudil (10-50 mM) caused qualitatively similar inhibition of growth to that caused by Y-27632. Again the compound caused increased apoptosis in a dose-dependant manner, with apoptosis equivalent to Y-27632 (20% at a concentration of 50 mM), and was observed to inhibit cell division using either BrDU assay or morphological assessment (n ¼ 3) (the results of BrDU analysis are shown in Figure 5 ). Given the reported safety of fasudil in clinical trials in humans, this suggests a therapeutic window that would allow CML-specific toxicity, without suppressing normal haematopoiesis. These findings, with a second specific r-kinase inhibitor, therefore confirm the specificity of our results obtained with Y-27632. Overall, our findings suggest that the abnormal activation of r-kinase in CML may play a role in the abnormal proliferation and survival of CML progenitor cells, and that the abnormal growth is opposed when cells are treated with specific r-kinase inhibitors. The findings we report were made using CD34 þ CML progenitor cells; the effectiveness of r-kinase inhibition in controlling the growth of this cell population is analogous to the effectiveness demonstrated by imatinib in pre-clinical studies, 22 suggesting that the inhibitory effects of r-kinase inhibitors we have reported will be clinically relevant. However, the effectiveness of the agents against more primitive stem cell populations in CML has not been tested in the studies we have described, if this occurs then this may be relevant to the capacity of r-kinase inhibitors to contribute to eliminating the abnormal clone in CML. 23, 24 These investigations will form part of followup studies that will be very relevant to the potential of these agents to contribute to the treatment of CML. In this regard, there is increasing interest in combining imatinib with either conventional or experimental therapeutic agents that may improve the effectiveness of treatment, and which may slow or prevent the advent of resistance to the drugs. 25 Our studies therefore highlight the potential for inhibitors of r-kinase to be used in the therapy of CML. Role q-kinase inhibitors and imatinib in CML J Burthem et al
